Ottimo Pharma Launches with Former Seagen CEO, Promising Cancer Drug Jankistomig

Ottimo Pharma has emerged from stealth with a strategic focus on innovative cancer therapies, led by former Seagen CEO David Epstein[1]. The company is dedicated to advancing Jankistomig, a PD1-VEGFR2 bifunctional antibody designed to enhance cancer treatment by targeting immune checkpoint inhibition and angiogenesis[1][2]. This promising candidate is positioned as a potential competitor to widely used immunotherapies like Keytruda, with an expected IND filing in 2025[1]. Backed by Medicxi, and assembled with industry veterans like Mehdi Shahidi and James Sabry, Ottimo aims to revolutionize cancer immunotherapy through its novel targeting mechanisms[2].